BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Huntington's Disease readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Huntington's Disease\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06312189-9342@assetmemo.bio
DTSTAMP:20261121T005019Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Ingrezza (Valbenazine): Phase 3 readout est. (NCT06312189)
DESCRIPTION:Ingrezza (Valbenazine)\, phase 3\, Huntington's Disease.\nStudy
 : Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Pa
 rticipants With Chorea Associated With Huntington Disease in Canada\nEstim
 ated primary completion: April 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/valbenazine#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06312189
URL:https://assetmemo.bio/drug/valbenazine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05243017-10915@assetmemo.bio
DTSTAMP:20261121T005019Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Ifezuntirgene inilparvovec: Phase 1/2 readout est. (NCT05243017)
DESCRIPTION:Ifezuntirgene inilparvovec\, phase 1/2\, Huntington's Disease.\
 nStudy: Safety and Efficacy of AMT-130 in European Adults With Early Manif
 est Huntington's Disease\nEstimated primary completion: March 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/ifezuntirgene-inilparvovec#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0524
 3017
URL:https://assetmemo.bio/drug/ifezuntirgene-inilparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04120493-10915@assetmemo.bio
DTSTAMP:20261121T005019Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Ifezuntirgene inilparvovec: Phase 1/2 readout est. (NCT04120493)
DESCRIPTION:Ifezuntirgene inilparvovec\, phase 1/2\, Huntington's Disease.\
 nStudy: Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults Wit
 h Early Manifest Huntington's Disease\nEstimated primary completion: June 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/ifezuntirgene-i
 nilparvovec#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT04120493
URL:https://assetmemo.bio/drug/ifezuntirgene-inilparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06254482-11257@assetmemo.bio
DTSTAMP:20261121T005019Z
DTSTART;VALUE=DATE:20290716
DTEND;VALUE=DATE:20290717
SUMMARY:Votoplam: Phase 2 readout est. (NCT06254482)
DESCRIPTION:Votoplam\, phase 2\, Huntington's Disease.\nStudy: An Extension
  Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Partic
 ipants With Huntington's Disease (HD)\nEstimated primary completion: 16 Ju
 ly 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/votoplam#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0625448
 2
URL:https://assetmemo.bio/drug/votoplam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07326709-11257@assetmemo.bio
DTSTAMP:20261121T005019Z
DTSTART;VALUE=DATE:20300402
DTEND;VALUE=DATE:20300403
SUMMARY:Votoplam: Phase 3 readout est. (NCT07326709)
DESCRIPTION:Votoplam\, phase 3\, Huntington's Disease.\nStudy: A Study to I
 nvestigate the Efficacy\, Safety and Tolerability of Votoplam in Participa
 nts With Huntington's Disease\nEstimated primary completion: 2 April 2030.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/votoplam#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07326709
URL:https://assetmemo.bio/drug/votoplam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
